- Home
- IBRX vs KARO Comparison
IBRX vs KARO Comparison
Compare IBRX & KARO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- KARO
- Stock Information
- Founded
- IBRX 2014
- KARO 2001
- Country
- IBRX United States
- KARO Singapore
- Employees
- IBRX N/A
- KARO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- KARO Computer Software: Prepackaged Software
- Sector
- IBRX Health Care
- KARO Technology
- Exchange
- IBRX Nasdaq
- KARO Nasdaq
- Market Cap
- IBRX 2.4B
- KARO 1.9B
- IPO Year
- IBRX N/A
- KARO 2021
- Fundamental
- Price
- IBRX $2.87
- KARO $47.34
- Analyst Decision
- IBRX Strong Buy
- KARO Buy
- Analyst Count
- IBRX 5
- KARO 2
- Target Price
- IBRX $11.40
- KARO $47.50
- AVG Volume (30 Days)
- IBRX 10.1M
- KARO 107.0K
- Earning Date
- IBRX 08-11-2025
- KARO 07-17-2025
- Dividend Yield
- IBRX N/A
- KARO 2.29%
- EPS Growth
- IBRX N/A
- KARO 24.98
- EPS
- IBRX N/A
- KARO 1.60
- Revenue
- IBRX $31,222,000.00
- KARO $245,745,961.00
- Revenue This Year
- IBRX $567.98
- KARO $18.73
- Revenue Next Year
- IBRX $160.56
- KARO $14.86
- P/E Ratio
- IBRX N/A
- KARO $29.39
- Revenue Growth
- IBRX 10238.41
- KARO 8.61
- 52 Week Low
- IBRX $1.83
- KARO $25.80
- 52 Week High
- IBRX $7.63
- KARO $63.36
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- KARO 41.69
- Support Level
- IBRX $2.77
- KARO $45.20
- Resistance Level
- IBRX $3.24
- KARO $60.95
- Average True Range (ATR)
- IBRX 0.23
- KARO 3.21
- MACD
- IBRX -0.03
- KARO -1.68
- Stochastic Oscillator
- IBRX 19.74
- KARO 11.78
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About KARO Karooooo Ltd.
Karooooo Ltd is a provider of real-time mobility data analytics solutions for smart transportation. It offers a comprehensive, cloud-based smart mobility platform for connected vehicles and other assets. The company's software-as-a-service platform provides customers with differentiated insights and analytics to optimize business and workforce, increase efficiency and decrease costs, improve safety, monitor environmental impact, assist with regularity compliance, and manage risk. The segments of the group are Cartrack; Carzuka; and Karooooo Logistics, of which key revenue is derived from the Cartrack segment.